Solid Tumor
Conditions
Brief summary
This open-label, non-randomized trial will comprise of 2 parts. A dose escalation part will characterize the safety, biomarker and pharmacokinetics of OPB-111077 in advanced solid tumor. Subsequently, an expansion part will further evaluate the biomarker, safety, pharmacokinetics and antitumor activity of OPB-111077 in selected tumor types.
Detailed description
This trial is designed to determine the safety, tolerability, maximum tolerated dose and recommended dose of OPB-111077 administered orally 4-days on and 3-days off (3 weeks/cycle) to subjects with advanced solid tumor in the dose escalation part so that biomarkers, efficacy, and others can be evaluated at the recommended dose in an expeditious manner in the expansion part. The dose escalation part employs a 3+3 escalation design as a standard dose escalation design for a small sample size.
Interventions
DRUGOPB-111077
Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
Sponsors
Otsuka Pharmaceutical Co., Ltd.
Korea Otsuka Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Pathologically and/or cytologically confirmed advanced solid tumor 2. Patients who were refractory to standard therapy or for which there are no standard treatment options available 3. Age 20 to 80 years at the time of informed consent 4. Patients who, together with their partner, are willing and capable of using an appropriate method of contraception throughout the trial period and until at least 12 weeks after final IMP administration 5. Patients informed of the diagnosis of advanced solid tumor who are fully informed about the content of the study by the investigator or subinvestigator using the specified written consent form and other written explanation, and give written consent to participate in the study of their free will 6. Patients who are able to take oral medication
Exclusion criteria
1. Patients with symptomatic brain metastases 2. Patients who have not recovered from any prior therapy related toxicity deemed to be clinically significant at study entry, except for the test item defined in inclusion criteria. 3. Patients with active infections needing whole body therapy 4. Patients with positive hepatitis B surface (HBs) antigen or positive hepatitis C virus (HCV) antibody 5. Patients with positive human immunodeficiency virus (HIV) antibody 6. Patients with uncontrollable cardiac diseases 7. Patients with uncontrollable pain by analgesic drugs 8. Patients with a history of organ transplantation 9. Patients who have received another IMP 10. Patients who are pregnant, possibly pregnant, or lactating 11. Patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 21 days | Number of participants with Adverse Events |
| Maximum tolerated dose | 21 days | The highest dose that does not lead to discontinuation of dose escalation |
| Biomarker of OPB-111077 | 21 days | Change from baseline on predictable biomarker specified in the protocol |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tumor response measured by RECIST(Response Evaluation Criteria in Solid Tumor) 1.1 Assessment | 3~18 weeks depending on tumor response | Tumor response measured by RECIST(Response Evaluation Criteria in Solid Tumor) 1.1 Assessment will be conducted at Screening, end of Cycle 1, end of Cycle 2, end of every 2 cycles thereafter, at the final study visit. |
| Pharmacokinetics (PK) properties of OPB-111077 and its metabolites. | 21 days | The following PK parameters (Cmax (maximum observed concentration), AUC(area uder the concentration time curve from zero), tmax (Time to maximum plasma concentration), etc.) will be determined using a non-compartmental methods. |
Countries
South Korea
Outcome results
None listed